ASAQ – DNDi

Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: A literature review and meta-analysis of individual patient data

by WWARN (ACT) Africa Baseline Study Group – includes Kiechel as co-author.

BioMed Central Medicine, September 2015

The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: A meta-analysis of individual patient data

by The Worldwide Antimalarial Resistance Network (WWARN) AS-AQ Study Group including Diap G, Kiechel JR, Sharma B.

BMC Medicine, March 2015

Availability and price of malaria rapid diagnostic tests in the public and private health sectors in 2011: Results from 10 nationally representative cross-sectional retail surveys

by Poyer S, Shewchuk T, Tougher S, Ye Y; ACTwatch Group, Mann AG, Willey BA, Thomson R, Amuasi JH, Ren R, Wamukoya M, Taylor M, Nguah SB, Mberu B, Kalolella A, Juma E, Festo C, Johanes B, Diap G, Bruxvoort K, Ansong D, Hanson K, Arnold F, Goodman C.

Trop Med Int Health, February 2015

Fixed dose artesunate amodiaquine – A phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine

by Ogutu B, Juma E, Obonyo C, Jullien V, Carn G, Vaillant M, Taylor WRJ, Kiechel JR.

Malaria Journal, December 2014

Polymorphisms in plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: Parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine

by Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, Price RN, Mårtensson A, Rosenthal PJ, Dorsey G, Sutherland CJ, Guérin P, Davis TME, Ménard D, Adam I, Ademowo G, Arze C, Baliraine FN, Berens-Riha N, Björkman A, Borrmann S, Checchi F, Desai M, Dhorda M, Djimdé AA, El-Sayed BB, Eshetu T, Eyase F, Falade C, Faucher JF, Fröberg G, Grivoyannis A, Hamour S, Houzé S, Johnson J, Kamugisha E, Kariuki S, Kiechel JR, Kironde F, Kofoed PE, LeBras J, Malmberg M, Mwai L, Ngasala B, Nosten F, Nsobya SL, Nzila A, Oguike M, Dahlström Otienoburu S, Ogutu B, Ouédraogo JB, Piola P, Rombo L, Schramm B, Somé AF, Thwing J, Ursing J, Wong RPM, Zeynudin A, Zongo I, Plowe CV, Hopkins Sibley C.

The American Journal of Tropical Medicine and Hygiene, July 2014

Plasmodium falciparum clearance in clinical studies of artesunate-amodiaquine and comparator treatments in sub-Saharan Africa, 1999–2009

by Zwang J, Dorsey G, Mårtensson A, d’Alessandro U, Ndiaye JL, Karema C, Djimde A, Brasseur P, Sirima SB, Olliaro P.

Malaria Journal, March 2014

Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: An open-label randomized non-inferiority trial

by Schramm B, Valeh P, Baudin E, Mazinda CS, Smith R, Pinoges L, Sundaygar T, Zolia YM, Jones JJ, Comte E, Bruneel A, Branger M, Jullien V, Carn G, Kiechel J, Ashley EA, and Guérin PJ.

Malaria Journal, July 2013

Tolerability and safety of artesunate-amodiaquine and artemether-lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: Two open-label, randomized trials in Nimba County, Liberia

by Schramm B, Valeh P, Baudin E, Mazinda CS, Smith R, Pinoges L, Sundaygar T, Zolia YM, Jones JJ, Comte E, Bruneel A, Branger M, Jullien V, Carn G, Kiechel JR, Ashley EA and Guérin PJ.

Malaria Journal, July 2013

Access to Artemisinin-Combination Therapy (ACT) and other anti-malarials: National policy and markets in Sierra Leone

by Amuasi JH, Diap G, Blay Nguah S, Karikari P, Boakye I, Jambai A, Kumba Lahai W, Louie KS, Kiechel JR.

PLoS one, October 2012

Clinical tolerability of artesunate-amodiaquine versus comparator treatments for uncomplicated falciparum malaria: an individual-patient analysis of eight randomized controlled trials in sub-Saharan Africa

by Zwang J, Dorsey G, Djimdé A, Karema C, Mårtensson A, Ndiaye JL, Sirima SB, Olliaro P. Malar J.

Malaria Journal, August 2012

Artesunate-amodiaquine fixed dose combination for the treatment of Plasmodium falciparum malaria in India

by Anvikar AR, Sharma B, Shahi BH, Tyagi PK, Bose TK, Sharma SK, Srivastava P, Srivastava B, Kiechel JR, Dash AP, Valecha N.

Malaria Journal, March 2012

Comparing changes in haematologic parameters occurring in patients included in randomized controlled trials of artesunate-amodiaquine vs single and combination treatments of uncomplicated falciparum in sub-Saharan Africa

by Zwang J, Ndiaye JL, Djimde A, Dorsey G, Martensson A, Karema C, Olliaro P.

Malaria Journal, January 2012

Hematologic parameters in pediatric uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa

by Olliaro P, Djimdé A, Dorsey G, Karema C, Mårtensson A, Ndiaye JL, Sirima SB, Vaillant M, Zwang.

J Am J Trop Med Hyg, Oct 2011

Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the ASAQ Winthrop experience

by Bompart F, Kiechel JR, Sebbag R, Pecoul B.

Malaria Journal, May 2011

The initial pharmaceutical development of an artesunate/amodiaquine oral formulation for the treatment of malaria: a public-private partnership

by Lacaze C, Kauss T, Kiechel JR, Caminiti A, Fawaz F, Terrassin L, Cuart S, Grislain L, Navaratnam V, Ghezzoul B, Gaudin K, White NJ, Olliaro P, Millet P.

Malaria Journal, May 2011